We are live on ! Find out more
Cambridge Investment Research Advisors

Cambridge Investment Research Advisors Portfolio holdings

AUM $44.6B
1-Year Est. Return 28.94%
This Fund
S&P 500
This Quarter Est. Return
-3.27%
1 Year Est. Return
+28.94%
3 Year Est. Return
+82.62%
5 Year Est. Return
+90.41%
10 Year Est. Return
+293.66%
AUM
$21.8B
AUM Growth
-$587M
Cap. Flow
+$493M
Cap. Flow %
2.27%
Top 10 Hldgs %
19.92%
Holding
3,387
New
221
Increased
1,507
Reduced
1,346
Closed
231

Sector Composition

Rank Sector Weight
1 Technology 9.85%
2 Financials 4.83%
3 Consumer Discretionary 4.67%
4 Healthcare 3.78%
5 Industrials 2.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TRX icon
3126
TRX Gold Corp
TRX
$360M
$14K ﹤0.01%
45,300
+9,000
+25% +$3.32K
SMTS
3127
DELISTED
Sierra Metals Inc. Common Stock
SMTS
$14K ﹤0.01%
11,621
ASXC
3128
DELISTED
Asensus Surgical, Inc.
ASXC
$13K ﹤0.01%
20,971
-5,000
-19% -$3.85K
NERV icon
3129
Minerva Neurosciences
NERV
$187M
$12K ﹤0.01%
1,738
ALLG.WS
3130
DELISTED
Allego N.V. Warrants
ALLG.WS
$11K ﹤0.01%
+10,000
New +$11.8K
ASAP
3131
DELISTED
Waitr Holdings Inc. Common Stock
ASAP
$11K ﹤0.01%
1,445
-62
-4% -$642
PTE
3132
DELISTED
PolarityTE, Inc. Common Stock
PTE
$11K ﹤0.01%
1,855
CNSP icon
3133
CNS Pharmaceuticals
CNSP
$7.32M
0
NRXPW
3134
DELISTED
NRX Pharmaceuticals Warrant
NRXPW
$9K ﹤0.01%
10,000
-19,450
-66% -$28.7K
TTOO
3135
DELISTED
T2 Biosystems, Inc
TTOO
$9K ﹤0.01%
4
HEXO
3136
DELISTED
HEXO Corp. Common Shares
HEXO
$9K ﹤0.01%
1,064
-9
-0.8% -$77
DCOY
3137
Decoy Therapeutics
DCOY
$1.92M
$8K ﹤0.01%
+1
New +$15.8K
TLPH icon
3138
Talphera
TLPH
$72.7M
$8K ﹤0.01%
1,409
+500
+55% +$4.23K
TXMD icon
3139
TherapeuticsMD
TXMD
$24.1M
$8K ﹤0.01%
432
+92
+27% +$1.45K
NXTP
3140
DELISTED
NextPlay Technologies, Inc. Common Stock
NXTP
$8K ﹤0.01%
750
GPL
3141
DELISTED
Great Panther Mining Limited
GPL
$6K ﹤0.01%
2,378
TYME
3142
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
$5K ﹤0.01%
14,000
GUT.RT
3143
DELISTED
The Gabelli Utility Trust Rights (expiring April 19, 2022)
GUT.RT
$5K ﹤0.01%
+26,145
New +$4.67K
TALKW
3144
DELISTED
Talkspace Inc Warrant
TALKW
$3K ﹤0.01%
10,550
NEPT
3145
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$3K ﹤0.01%
9
TBLT
3146
DELISTED
ToughBuilt Industries, Inc. Common Stock
TBLT
$2K ﹤0.01%
1
AAOI icon
3147
Applied Optoelectronics
AAOI
$11.7B
-11,280
Closed -$58K
AAP icon
3148
Advance Auto Parts
AAP
$3.23B
-1,903
Closed -$457K
ACIC icon
3149
American Coastal Insurance
ACIC
$465M
-10,000
Closed -$43K
ADEA icon
3150
Adeia
ADEA
$3.1B
-53,483
Closed -$268K

Similar funds

Cambridge Investment Research Advisors's Q1 2022 Portfolio in Review

As of Q1 2022, Cambridge Investment Research Advisors held 3,387 positions worth $21.8B, down 2.6% from $22.4B the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Cambridge Investment Research Advisors's Q1 2022 filing shows 221 new, 1,507 increased, 1,346 reduced and 231 closed positions. Its largest new stake was Alarm.com: 285,954 shares worth $19M. The largest sale was iShares Core S&P US Growth ETF, an estimated $43.9M.

By sector, the portfolio is most concentrated in Technology at 9.9% of assets, down from 10% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Cambridge Investment Research Advisors's largest Q1 2022 buy was Alarm.com: 285,954 shares worth $19M.
  • Cambridge Investment Research Advisors added most to iShares 0-1 Year Treasury Bond ETF in Q1 2022, an estimated $52.6M increase.
  • Cambridge Investment Research Advisors's biggest Q1 2022 reduction was iShares Core S&P US Growth ETF, cutting an estimated $43.9M.
  • Cambridge Investment Research Advisors fully exited Royal Dutch Shell PLC ADS Class A in Q1 2022, selling an estimated $3.6M.
  • Cambridge Investment Research Advisors's ten largest holdings make up 20% of its $21.8B portfolio in Q1 2022.
  • Cambridge Investment Research Advisors opened 221 new positions and closed 231 in Q1 2022.
  • Cambridge Investment Research Advisors's portfolio value fell 2.6% quarter-over-quarter to $21.8B.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2022, filed 12 May 2022.